Health Economic Burden of COVID-19 and its Comorbidities in India: An Exploratory Study
Introduction: COVID-19’s economic impact is crucial for adding merits to the policymaking process. This study was designed to evaluate the economic burden (direct medical cost) on COVID-19 patients and compare the treatment cost of patients with and without comorbidities at a tertiary hospital, as well as assess the prevalence of comorbidities associated with COVID-19 patients.
Methods: The analysis was retrospectively conducted at National Heart Institute, New Delhi between June 1, 2020 and November 30, 2020. The study included diagnosed COVID-19 patients who were admitted to the hospital during these 6 months. The patient’s demographics, hospitalisation characteristics, and coexisting medical conditions were all evaluated.
Results: The total direct medical costs were evaluated by cost factors. In this study, the demography of patients was recorded and found that out of 400 patients, 260 (65%) were male and 140 (35%) were female. 294 patients had at least one pre-existing disease. Finally, 360 (90%) subjects recovered whereas, 40 (10%) died. The overall mean cost per COVID-19 treatment episode was found to be INR 264,703.
Conclusion: The findings of this study demonstrated that the disease’s severe condition resulted in an exceptionally high cost of illness.
How to cite this article:
Gupta A, Sharma A, Patil CR, Sharma V, Mittal N, Devi S. Health Economic Burden of COVID-19 and its Comorbidities in India: An Exploratory Study. J Commun Dis. 2023;55(2):91-96.
Darab MG, Keshavarz K, Sadeghi E, Shahmohamadi J, Kavosi Z. The economic burden of coronavirus disease
(COVID-19): evidence from Iran. BMC Health Serv Res. 2021;21(1):132. [PubMed] [Google Scholar]
Tiwari, S., Kumar, S., & Guleria, K. (2020). Outbreak trends of coronavirus disease–2019 in India: a
prediction. Disaster medicine and public health preparedness, 14(5), e33-e38.[PubMed] [Google
Jin H, Wang H, Li X, Zheng W, Ye S, Zhang S, Zhou J, Pennington M. Economic burden of COVID-19, China,
January–March, 2020: a cost-of-illness study. Bull World Health Organ. 2021;99(2):112-24. [PubMed] [Google
Mølhave M, Agergaard J, Wejse C. Clinical management of COVID-19 patients–an update. Semin Nucl Med. 2022 Jan;52(1):4-10. [PubMed] [Google Scholar]
Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, Van Weel
C, Zielinski J; Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis,
management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am
J Respir Crit Care Med. 2007 Sep 15;176(6):532-55. [PubMed] [Google Scholar]
Ozkendir OM, Askar M, Kocer NE. Influence of the epidemic COVID-19: an outlook on health, business and
scientific studies. Lab Silico. 2020 Jun 30;1(1):26-30.
Harrison SL, Fazio-Eynullayeva E, Lane DA, Underhill P, Lip GY. Comorbidities associated with mortality in
,461 adults with COVID-19 in the United States: a federated electronic medical record analysis. PLoS
Med. 2020;17(9):e1003321. [PubMed] [Google Scholar]
Nagu P, Parashar A, Behl T, Mehta V. CNS implications of COVID-19: a comprehensive review. Reviews in the
Neurosciences. 2021 Feb 1;32(2):219-34. [PubMed] [Google Scholar]
Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM, Liu XQ, Chen RC, Tang CL, Wang T, Ou CQ, Li L, Chen
PY, Sang L, Wang W, Li JF, Li CC, Ou LM, Cheng B, Xiong S, Ni ZY, Xiang J, Hu Y, Liu L, Shan H, Lei CL, Peng YX,
Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Cheng
LL, Ye F, Li SY, Zheng JP, Zhang NF, Zhong NS, He JX; China Medical Treatment Expert Group for COVID-19.
Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J.
May;55(5):2000547. [PubMed] [Google Scholar]
Divo MJ, Casanova C, Marin JM, Pinto-Plata VM, DeTorres JP, Zulueta JJ, Cabrera C, Zagaceta J, SanchezSalcedo P, Berto J, Davila RB, Alcaide AB, Cote C, Celli BR; BODE Collaborative Group. COPD comorbidities network. Eur Respir J. 2015 Sep;46(3):640-50. [PubMed] [Google Scholar]
Jeck J, Jakobs F, Kron A, Franz J, Cornely OA, Kron F. A cost of illness study of COVID-19 patients andretrospective modelling of potential cost savings when administering remdesivir during the pandemic “first
wave” in a German tertiary care hospital. Infection. 2022;50(1):191-201. [PubMed] [Google Scholar]
Haitao T, Vermunt JV, Abeykoon J, Ghamrawi R, Gunaratne M, Jayachandran M, Narang K,
Parashuram S, Suvakov S, Garovic VD. COVID-19 and sex differences: mechanisms and biomarkers. Mayo
Clin Proc. 2020;95(10):2189-203. [PubMed] [Google Scholar]
Maltezou HC, Giannouchos TV, Pavli A, Tsonou P, Dedoulou X, Tseroni M, Papadima K, Hatzigeorgiou D,
Sipsas NV, Souliotis K. Costs associated with COVID-19 in healthcare personnel in Greece: a cost-of-illness
analysis. J Hosp Infect. 2021 Aug;114:126-33. [PubMed] [Google Scholar]
Khan AA, AlRuthia Y, Balkhi B, Alghadeer SM, Temsah MH, Althunayyan SM, Alsofayan YM. Survival and
estimation of direct medical costs of hospitalized COVID-19 patients in the Kingdom of Saudi Arabia. Int
J Environ Res Public Health. 2020 Oct 13;17(20):7458. [PubMed] [Google Scholar]
Di Fusco M, Shea KM, Lin J, Nguyen JL, Angulo FJ, Benigno M, Malhotra D, Emir B, Sung AH, Hammond JL,
Stoychev S, Charos A. Health outcomes and economic burden of hospitalized COVID-19 patients in the United
States. J Med Econ. 2021;24(1):308-17. [PubMed] [Google Scholar]
John D, Narassima MS, Menon J, Rajesh JG, Banerjee A. Estimation of the economic burden of COVID-19 using
disability-adjusted life years (DALYs) and productivity losses in Kerala, India: a model-based analysis. BMJ
Open. 2021 Aug 18;11(8):e049619. [PubMed] [Google Scholar]
Kumar P, Kumar M, Bedi O, Gupta M, Kumar S, Jaiswal G, Rahi V, Yedke NG, Bijalwan A, Sharma S,
Jamwal S. Role of vitamins and minerals as immunity boosters in COVID-19. Inflammopharmacology. 2021
Aug;29(4):1001-16. [PubMed] [Google Scholar]
Mahajan P, Kaushal J. Epidemic trend of COVID-19 transmission in India during lockdown-1 phase.
J Community Health. 2020 Dec;45(6):1291-300. [PubMed] [Google Scholar]
Mittal N, Garg V, Bhadada SK, Katare OP. Role of novel drug delivery systems in Coronavirus disease-2019
(COVID-19): time to act now. Curr Drug Deliv. 2021;18(3):289-96. [PubMed] [Google Scholar]
Copyright (c) 2023 Author's
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.